Irlab Therapeutics Ab Class A · OMXSTO:IRLAB_A
Irlab Therapeutics Ab Class A — Q2 2025 Earnings Presentation
30 slides from Irlab Therapeutics Ab Class A's earnings presentation, September 2025
Slide 1: World leader - developing new treatments for Parkinson's disease
World leader - developing new treatments for Parkinson's disease IRLAB, Q2 2025 ©2025 ©2025 IRLAB Therapeutics AB (publ), AllIRLAB rightsTherapeutics reserved AB (publ), All rights reserved
Slide 2: Disclaimer
Disclaimer This document, “IRLAB Therapeutics” (the “Presentation”), has been prepared by IRLAB Therapeutics AB (publ) (“IRLAB”) and is provided for informational purposes only. All information in this Presentation has been compiled in good faith by IRLAB. Neither IRLAB nor any of its directors, emp
Slide 3: Today's agenda
Today’s agenda 1 News in the period Kristina Torfgård, CEO 4 Concluding words 2 R&D update Nicholas Waters, EVP Head of R&D 3 Financials 5 Q&A session Viktor Siewertz, CFO ©2025 IRLAB Therapeutics AB (publ), All rights reserved 3
Slide 4: Key highlights in and after Q2 2025
Key highlights in and after Q2 2025 New patent granted for mesdopetam – expands patent protection in Strengthening the value of the US and expires in the mid 2040s mesdoptam IRL757 progresses according Positive Phase I results on IRL757 support ongoing development to plan – fully funded through clin
Slide 5: R&D update
am | TRLAB It R&D update
Slide 6: Mesdopetam
Mesdopetam IRL790 Treating levodopa-induced dyskinesias (PD-LIDs) through a novel mechanism – Dopamine D3 receptor antagonism ©2025 IRLAB Therapeutics AB (publ), All rights reserved
Slide 7: Mesdopetam (IRL790)
Mesdopetam (IRL790) Potential for patent- First in class- a novel Inhibiting dopamine D3 based exclusivity mechanism receptors towards mid 2040s “Pipeline-in-a-Pill” - life cycle management opportunities • Parkinson disease psychosis Lead indication – levodopa-induced • Prevention of levodopa-induce
Slide 8: Regulatory validation and value creation Q1 & Q2
Regulatory validation and value creation Q1 & Q2 Regulatory guidance and payor input on mesdopetam phase III program achieved • Scientific advice with EMA and local EU regulatory agencies in line with FDA advice on design of Phase III program Important value creating information & patents granted in
Slide 9: Mesdopetam fills the gap between current levodopa based and invasive treatments
Mesdopetam fills the gap between current levodopa based and invasive treatments PD Disease severity Pharmacological Invasive Levodopa adjustments + other concomitant treatments Produodopa Duodopa DBS (31 kGBP/yr) (28 kGBP/yr) (65 kUSD) payor position (ref: NICE) Advanced levodopa-responsive Mesdopet
Slide 10: Pirepemat
Pirepemat IRL752 • A treatment reduce falls in Parkinson’s (PD-Falls) • Full program from preclin through a randomized, placebo- controlled dose-finding Phase IIb clinical trial completed ©2025 IRLAB Therapeutics AB (publ), All rights reserved
Slide 11: Pirepemat (IRL752)
Pirepemat (IRL752) Potential for patent- First in class - a novel Inhibiting alpha 2 and based exclusivity mechanism serotonin 7 receptors towards mid-2040s Objective – reduce falls in Parkinson’s disease ©2025 IRLAB Therapeutics AB (publ), All rights reserved 11
Slide 12: Pirepemat - in development to reduce falls in Parkinson's
Pirepemat - in development to reduce falls in Parkinson’s A huge unmet need Reducing falls is the greatest medical need and one of the most complicating aspects of Parkinson’s EU5 • 45% of individuals with Parkinson’s fall recurrently (DE, ES, FR, IT, • Cost of a fall injury approx. 30 000 USD in pa
Slide 13: Reduction in relative fall rate vs. pirepemat plasma concentration
Reduction in relative fall rate vs. pirepemat plasma concentration [exposure]: PK-PD 100 Prespecified assessment of exposure vs. efficacy - therapeutic window 90 Study participants were assigned to three groups of same size based on plasma 80 22 concentration [exposure] and compared to the 30 partic
Slide 14: Developments during Q2
Developments during Q2 Status and ongoing activities • Based on the dose finding phase IIb data a strengthened development plan in place • Preparing for a decision on the next step in the development of pirepemat – including; • Preparation for a clinical study with the aim to optimize the titration
Slide 15: IRL757 – treatment of apathy
IRL757 – treatment of apathy Apathy: loss of initiative, interest, and emotional expression/responsiveness • A novel first-in-class treatment for apathy in neurological disorders Addressable population: 2-7 million people ©2025 IRLAB Therapeutics AB (publ), All rights reserved
Slide 16: IRL757 is aimed at the huge untreated problem with apathy
IRL757 is aimed at the huge untreated problem with apathy Apathy Loss of initiative, interest and emotional Huge unmet medical need expression/ responsiveness, often found in people • Several million US and EU citizens may be affected by with dementia. apathy • Apathy occurs in 20-70% in people with
Slide 17: IRL757 project progress in Q1
IRL757 project progress in Q1 IRL757 has the potential to be the first drug in a new class to treat apathy in Parkinson’s and other neurological disorders • Funding to conduct the Phase I (SAD & MAD) study with IRL757 is secured in through the Michael J. Fox Foundation • Collaboration with MSRD/Otsu
Slide 18: Preclinical projects
Preclinical projects IRL942 Clinical candidate - Improve cognitive function IRL1117 Clinical candidate - Once-daily oral treatment of Parkinson’s without troublesome complications ©2025 IRLAB Therapeutics AB (publ), All rights reserved
Slide 19: Innovative preclinical pipeline with first-in-class NCEs
Innovative preclinical pipeline with first-in-class NCEs IRL942 IRL1117 Improvement of cognitive function Next generation Parkinson’s treatment Memory, perception, Once-daily attention, reasoning, Parkinson’s hallmark symptoms problem-solving and (tremor, rigidity, bradykinesia) decision-making With
Slide 20: IRL942 to improve cognitive function in PD and other neurological indications
IRL942 to improve cognitive function in PD and other neurological indications • Unmet need among a large population Cognition • 12 % of adults aged 65 years or more experience cognitive decline Cognition encompasses all (CDC) aspects of intellectual • Studies demonstrate a high cumulative risk of de
Slide 21: IRL942 project progress in Q2
IRL942 project progress in Q2 IRL942 has the potential to be the first drug in a new class to improve the cognitive function in people living with Parkinson’s and other neurological disorders Status • GMP manufacturing of the drug substance and development of the method for drug product production i
Slide 22: IRL1117 – potential to be the first drug in a new class to treat Parkinson's
IRL1117 – potential to be the first drug in a new class to treat Parkinson’s Status • IRL1117 is a potent dopamine D1 and D2 receptor 80 Vehicle agonist IRL1117 0.1μmol/ kg • The preclinical results from long-term treatment show 60 that IRL1117 has full anti-Parkinson effect with clear Motor activat
Slide 23: Finance report Q2 2025
Finance report Q2 2025 • Highlights and summary • Analyst coverage
Slide 24: Financial highlights
Financial highlights • Cash position SEK 54 million. Roughly 56 million (gray bar in left graph below) will be added from the rights issue that was announced in Q2 and concluded in Q3. • External clinical cost continues to decrease. Most of the quarter’s cost occurred during April. • Partnering cost
Slide 25: Financial summary
Financial summary Q1-Q2 Q1-Q2 2025 2024 Net sales, SEK 23.9m 42.8 Operating profit, SEK - 54.4m - 42.7m Earnings per share before and after dilution, SEK - 1.28 - 0.89 Cash and cash equivalents, SEK 53.6m 98.3m Cash flow from operating activities, SEK - 36.3m - 38.1m Average number of employees 31 3
Slide 26: Remarkable advances from 2013 until today
Remarkable advances from 2013 until today • The company started in 2013 with two preclinical projects and the development platform ISP • Today we have five projects, three of which are in clinical stage and some even in late clinical stage • Organizational momentum has been build going from a handfu
Slide 27: Concluding words
am | TRLAB It Concluding words
Slide 28: World leading portfolio of development programs for Parkinson's disease
World leading portfolio of development programs for Parkinson’s disease Discovery Preclinical Phase I Phase IIa Phase IIb Phase III Next major event Parkinson’s disease levodopa- Phase III Mesdopetam induced dyskinesia (PD-LIDs) 2025: ready (IRL790) D3 antagonist Projected start of Phase III study P
Slide 29: Value creation milestones over the next 12-18 months
Value creation milestones over the next 12-18 months • BD activities Mesdopetam • Initiation of the Phase III program • Decision on next step – prepare for dose Pirepemat optimization study • BD activities • Start the study in PD-apathy (Phase Ib safety IRL757 and efficacy signal finding) • IRL942:
Slide 30: Contact
Contact: Kristina Torfgård, CEO, kristina.torfgard@irlab.se Nicholas Waters, EVP and Head of R&D, nicholas.waters@irlab.se Viktor Siewertz, CFO, viktor.siewertz@irlab.se IRLAB discovers and develops a portfolio of transformative treatments for all stages of Parkinson’s disease. The company originate